Introduction {#Sec1}
============

*Mycobacterium tuberculosis* is the main cause of death due to a single infectious agent (World Health Organisation [@CR42]) among humans, and as many as 2 billion people worldwide are infected with tuberculosis (for a review, see Takayama et al. [@CR38] and references cited therein). In light of the rise in mycobacterial resistance toward isoniazid, which represents one of less than a handful of first-line antituberculous drugs, there is an urgent need to widen the study of vital *M. tuberculosis* processes so as to develop novel drugs.

Isoniazid targets the production of mycolic acids (Banerjee et al. [@CR3]), which are very long-chain α-branched β-hydroxylated fatty acids (C~54--63~) that help form the protective layer around this pathogen, thereby adding to its persistence and virulence (Takayama et al. [@CR38]). Mycolic acid biosynthesis involves a combination of an associative type 1 fatty acid synthase (FASI) similar to the system found in the eukaryotic cytosol, in that it comprises several enzymatic activities located on a single multifunctional synthase (Bloch [@CR7]) and a dissociative type 2 process (FASII) resembling the plant--plastid system that consists of separate enzymes. FASII also occurs in yeast mitochondria (reviewed in Hiltunen et al. [@CR26]).

In *M. tuberculosis* FASII, FabG1 (MabA) undertakes the reduction of 3-oxoacyl-acyl carrier protein (AcpM) to generate 3-hydroxyacyl-AcpM (Banerjee et al. [@CR4]), whereas in the equivalent mitochondrial process in *Saccharomyces cerevisiae,* this step is catalyzed by Oar1p (Schneider et al. [@CR37]). In reference to substrate specificities, FabG1 has been demonstrated previously to catalyze the NADP(H)-specific reduction of long-chain (C~8--20~) 3-oxoacyl-thioester species. Molecular modeling of FabG1 revealed a large substrate-binding pocket capable of accommodating long-chain substrates (Marrakchi et al. [@CR29]), while yeast Oar1p is presumed to act on only short-chain ones. Analysis of the complete sequence of the *M. tuberculosis* genome (Cole et al. [@CR12]) revealed FabG1 as having four homologs, termed FabG2--FabG5 (Fig. [1](#Fig1){ref-type="fig"}), but, so far, not one of them has been fully characterized.Fig. 1Homology study of *M. tuberculosis* FabG proteins. Multalin- and Genedoc-based comparison of the deduced amino acid sequence of FabG1 (Rv1483) with those of its homologs FabG2 (Rv1350), FabG3 (Rv2002), FabG4 (Rv0242c) and FabG5 (Rv2766c). *Dashes* indicate the arrangement of the sequences for best fit, and *arrows* point to the amino acids forming the catalytic triad (Marrakchi et al. [@CR29]). The first 150 amino acid residues of FabG4 do not match any of those of the other homologs, and were removed from the figure. *Black shadings* refer to strictly conserved amino acid residues among all the sequences, whereas the *darker* and *lighter grayshadings* denote regions with more relaxed residue similarities not necessarily shared by the full set of sequences

The essential requirement for FabG activity has been addressed before in a genome-wide survey using transposon-site hybridization, which revealed just over 600 *M. tuberculosis* genes that were required for optimal growth (Sassetti et al. [@CR36]), among them *fabG2/Rv1350*. However, a subsequent study identifying almost 200 *M. tuberculosis* genes that were required for mycobacterial survival during infection did not pick up a single *fabG* locus (Sassetti and Rubin [@CR35]). The dispute surrounding the requirement for 3-oxoacyl-thioester activity in mycobacteria was finally settled with the finding that FabG1 is in fact essential for *M. tuberculosis* survival (Parish et al. [@CR31]), whereas in *M. bovis* BCG, FabG1 and the hitherto uncharacterized FabG4 have both been exposed as being vital (Beste et al. [@CR5]).

The latter finding of two non-redundant FabGs in *M. bovis* BCG raised the pertinent question of whether a similar situation might also occur in *M. tuberculosis*, whereby FabG1 is not necessarily the sole essential 3-oxoacyl-thioester reductase after all. This prompted the deployment of an alternative strategy for studying the functions of the remaining four FabG homologs. To this end, *S. cerevisiae* was exploited as a surrogate host for investigating *M. tuberculosis* proteins (Gerum et al. [@CR17]) with potential FASII activities. Here, mitochondrially targeted versions of FabG1 to FabG5 were expressed in yeast *oar1*Δ mutant cells (Schneider et al. [@CR37]), which lack 3-oxoacyl-ACP reductase activity and do not respire or grow on glycerol, assemble cytochrome complexes or produce lipoic acid. The effects were compared to those of ectopically expressing native Oar1p. This *oar1*Δ strain was applied previously to expose the identity of nematode and human 3-oxoacyl-thioesters (Gurvitz [@CR19]; Chen et al. [@CR11]). The outcome of this study is discussed in terms of the identification of the essential mycobacterial *fabG4* gene as encoding a novel 3-oxoacyl-thioester reductase, as well as the role of protein--protein interactions in mycobacterial FASII.

Materials and methods {#Sec2}
=====================

*S. cerevisiae* strains, plasmids and oligonucleotides {#Sec3}
------------------------------------------------------

Yeast strains, plasmids and oligonucleotides used are listed in Table [1](#Tab1){ref-type="table"}. The *Escherichia coli* strain TOP10 F′ was used for all plasmid amplifications and isolations. The wild-type yeast strain BY4741 and its *oar1*Δ derivative were obtained from EUROSCARF ([www.uni-frankfurt.de](http://www.uni-frankfurt.de)). To generate strains yPLM37 to yPLM43, plasmids were introduced into BY4741*oar1*Δ cells using a published protocol (Chen et al. [@CR10]), and transformants were selected on solid synthetic defined glucose (SD-Ura) medium lacking uracil.Table 1*S. cerevisiae* strains, plasmids and oligonucleotides usedStrain, plasmid, oligonucleotideDescriptionSource or reference*S. cerevisiae* (1) BY4741*MAT***a***his3*Δ*1leu2*Δ*0met15*Δ*0ura3*Δ*0*EUROSCARF (2) BY4741*oar1*Δ^1a^*ykl055c::kanMX*EUROSCARF  yPLM37^2^Expressing peroxisomal catalase A (Cta1p) from pPLM187This study  yPLM38^2^Expressing mitochondrial Coq3p-FabG1 from pPLM189This study  yPLM39^2^Expressing mitochondrial Coq3p-FabG2 from pPLM190This study  yPLM40^2^Expressing mitochondrial Coq3p-FabG3 from pPLM191This study  yPLM41^2^Expressing mitochondrial Coq3p-FabG4 from pPLM192This study  yPLM42^2^Expressing mitochondrial Coq3p-FabG5 from pPLM193This study  yPLM43^2^Expressing mitochondrial Oar1p from pPLM188This studyPlasmid (3) pBluescript KS IIIpKS cloning vectorStratagene  pPLM83^3^pKS:Rv1483 mitochondrial *fabG1* in pBluescriptThis study  pPLM82^3^pKS:Rv1350 mitochondrial *fabG2* in pBluescriptThis study  pPLM86^3^pKS:Rv2002 mitochondrial *fabG3* in pBluescriptThis study  pPLM78^3^pKS:Rv0242c mitochondrial *fabG4* in pBluescriptThis study  pPLM96^3^pKS:Rv2766c mitochondrial *fabG5* in pBluescriptThis study (4) YEp352*URA3*-marked multicopy plasmidHill et al. ([@CR25]) (5) pPLM187^4^*CTA1* behind its promoter (pYE352:*CTA1*)Filppula et al. ([@CR16])  pPLM188^5^*OAR1* behind the *CTA1* promoter (pYE352:*OAR1*)Chen et al. ([@CR11]) (6) pPLM62^5^*COQ3-QOR* fusion behind the *CTA1* promoterTorkko et al. ([@CR39])  pPLM189^6^*COQ3-fabG1* fusion behind the *CTA1* promoterThis study  pPLM190^6^*COQ3-fabG2* fusion behind the *CTA1* promoterThis study  pPLM191^6^*COQ3-fabG3* fusion behind the *CTA1* promoterThis study  pPLM192^6^*COQ3-fabG4* fusion behind the *CTA1* promoterThis study  pPLM193^6^*COQ3-fabG5* fusion behind the *CTA1* promoterThis studyOligonucleotide Rv1483 MLS-FabG1 F5′-TTATCCATGGCTGCCACAGCCACTGAAGGGGC-3′This study Rv1483 FabG1 R5′-TATTAAGCTTCAGTGGCCCATACCCATGCC-3′This study Rv1350 MLS-FabG2 F5′-TTATCCATGGCGTCATTGCTGAACGCTC-3′This study Rv1350 FabG2 R5′-TATACTCGAGTCATATGAACCGGCCGCCAG-3′This study Rv2002 MLS-FabG3 F5′-TTATCCATGGCTGGACGGTTGATAGGAAAGG-3′This study Rv2002 FabG3 R5′-TATTAAGCTTACGTCACCCATTCCGGCTGCG-3′This study Rv0242c MLS-FabG4 F5′-TTATCCATGGCTCCCAAGCGTTCGTCCGATC-3′This study Rv0242c FabG4 R5′-TATTAAGCTTCACGCGCCGATCATGGCCTGGC-3′This study Rv2766c MLS-FabG5 F5′-TTATTATCATGACCTCACTGGATCTGACC-3′This study Rv2766c FabG5 R5′-TTATTATCATGACCTCACTGGATCTGACC-3′This study^a^The numbers in superscript following the designation of the strains refer to their parental genotypes, e.g., BY4741*oar1*Δ^1^ was derived from (1) BY4741. The same principle applies to plasmids

Plasmid constructions {#Sec4}
---------------------

DNA manipulations and plasmid constructions were performed according to standard techniques (Ausubel et al. [@CR2]). The five *fabG* genes were isolated from H37Rv genomic DNA by polymerase chain reaction (PCR) using Phusion high-fidelity DNA polymerase (Finnzymes Oy, Espoo, Finland) and the corresponding oligonucleotides (Table [1](#Tab1){ref-type="table"}), as described previously (Gurvitz et al. [@CR21],[@CR22], [@CR23]). Electrophoretic resolution of the PCR products, and their excision, purification and subsequent ligation to an *Eco*RV-digested pBluescript plasmid vector (Stratagene, La Jolla, CA) were performed as done previously (Gurvitz et al. [@CR22]). The five pBluescript inserts were subcloned following digestion with *Nco*I and *Hin*dIII restriction enzymes, and ligated behind the *CTA1* promoter within a similarly digested plasmid pYE352:*mitQOR* (pPLM62). As a result of this digestion, the *QOR* open reading frame (ORF) encoding *E. coli* quinone reductase was removed to leave behind the nucleotides for the yeast Coq3p (Hsu et al. [@CR27]) mitochondrial leader sequence (MLS), as described in the literature (Torkko et al. [@CR39]; Gurvitz et al. [@CR22]). Following import into the mitochondria, the fused MLS is cleaved off to leave behind a shorter fusion protein preceded by eight amino acids remaining from the MLS fusion (Torkko et al. [@CR39]). Nucleotide sequencing of the *fabG* inserts verified that no mutations were introduced during the amplification process and that the *COQ3-fabG* junction remained intact. Construction of plasmid YEp352:*OAR1* (pPLM188) expressing *S. cerevisiae* mitochondrial *OAR1* from the *CTA1* promoter is described (Chen et al. [@CR11]). Briefly, the *OAR1* ORF was amplified from yeast genomic DNA using standard procedure and, following digestion with the appropriate restriction enzymes, the PCR product was ligated to a similarly digested pYE352:*CTA1* (Filppula et al. [@CR16]), from which the *CTA1* ORF was removed (Chen et al. [@CR11]).

Media and growth conditions {#Sec5}
---------------------------

Standard yeast (Rose et al. [@CR32]) and *E. coli* (Sambrook et al. [@CR34]) media were prepared as described. *S. cerevisiae* strains were propagated on solid, rich glucose medium YPD consisting of 1% (wt/vol) yeast extract, 2% (wt/vol) peptone (YP), 2% (wt/vol) [d]{.smallcaps}-glucose and 2% (wt/vol) agar. YEp352-based episomal plasmids marked with the *URA3* gene (Hill et al. [@CR25]) were maintained in transformed strains on solid, synthetic defined (SD-Ura) medium consisting of 0.67% (wt/vol) yeast nitrogen base without amino acids, 2% (wt/vol) [d]{.smallcaps}-glucose and 3% (wt/vol) agar, with all necessary supplements added except for uracil (Sigma--Aldrich Inc., MO, USA). Synthetic complete glycerol (SCglycerol) medium was prepared essentially as SD-Ura, except that uracil was added and glucose was replaced with 3% (wt/vol) glycerol. Induction of yeast cells in oleic acid medium has been described previously (Gurvitz et al. [@CR20]).

Miscellaneous {#Sec6}
-------------

For 3-oxoacyl-thioester reductase activity assays, soluble protein extracts were prepared from yeast cells that were propagated in oleic acid medium and processed as described (Gurvitz et al. [@CR21],[@CR22], [@CR23]). Protein concentrations were determined according to a published method (Bradford [@CR8]). Reductase activity was assayed spectrophotometrically at 23°C as described (Dommes and Kunau [@CR13]). The reductase activity assay mixture consisted of 50 mM KP~i~ (pH 8.0) and 50 µg/ml bovine serum albumin, 2.0 µl purified protein representing the hydratase 2 domain from *Drosophila melanogaster* MFE2 (unpublished), 125 µM NADP^+^ or NAD^+^, and 60 µM 2-*trans*-decenoyl-CoA or 2-*trans*-hexenoyl-CoA that were synthesized via the mixed anhydride system (Goldman and Vagelos [@CR18]). Reduction of the electron carrier was monitored spectrophotometrically at 340--385 nm. The assembly of cytochrome complexes was followed with a spectrophotometer at 480--640 nm, using yeast cells that were applied as a thick paste onto the glass surface of an otherwise aluminum cold-temperature cuvette, which was chilled in liquid nitrogen (Lindenmayer and Estabrook [@CR28]). The lipoic acid content of yeast strains was monitored by a biological assay as described previously (Brody et al. [@CR9]; Hayden et al. [@CR24]). Operon prediction was undertaken using OperonDB (<http://operondb.cbcb.umd.edu/cgi-bin/operondb/operons.cgi>). Multalin (npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page =/NPSA/npsa_multalin.html) and Genedoc (www. nrbsc.org/gfx/genedoc/index.html) were used to generate the sequence comparison in Fig. [1](#Fig1){ref-type="fig"}.

Results {#Sec7}
=======

Mycobacterial FabG1 and FabG4 restore respiratory growth of *S. cerevisiae oar1*Δ cells {#Sec8}
---------------------------------------------------------------------------------------

The *M. tuberculosis* genome (Cole et al. [@CR12]) contains five genes with the potential to encode 3-oxoacyl-AcpM reductases, termed *fabG1* to *fabG5* (Takayama et al. [@CR38]). FabG1 is chronicled as a 3-oxoacyl-AcpM reductase involved in mycolic acid biosynthesis (Banerjee et al. [@CR4]; Marrakchi et al. [@CR29]); however, the function of the remaining four homologs has hitherto remained unknown. To determine whether these could encode 3-oxoacyl-thioester reductases, FabG1--FabG5 were expressed as fusion constructs that were preceded by the Coq3p mitochondrial leader sequence (Hsu et al. [@CR27]) so as to generate mitochondrially targeted versions. The five fusions were tethered behind the promoter of the *CTA1* gene encoding peroxisomal catalase A (Cta1p), which is only moderately de-repressed on non-fermentable carbon sources such the glycerol is used here for complementation assays (Filipits et al. [@CR15]; Rottensteiner et al. [@CR33]). These tests were performed on yeast cells lacking Oar1p that have been exploited previously to demonstrate the physiological function of ectopically expressed 3-oxoacyl-ACP reductases (Gurvitz [@CR19]; Chen et al. [@CR11]).

Mutant *oar1*Δ yeast cells were transformed with multicopy episomal plasmids loaded with the fusion constructs. Following selection on synthetic defined glucose medium lacking uracil (SD-Ura), survivors were streaked on synthetic complete medium containing glycerol (SCglycerol) as the sole carbon source. Only those mutants expressing FabG1 or FabG4 were capable of forming single colonies on this medium type. A dedicated analysis of the reasons for the failure of FabG2, FabG3 or FabG5 to achieve phenotype rescue was beyond the scope of the present study, these causes being all the more enigmatic since no obvious differences among the homologs emerged from the data shown in Fig. [1](#Fig1){ref-type="fig"}.

To demonstrate more accurately that expression of mitochondrial versions of FabG1 or FabG4 in the *oar1*Δ mutant cells could compensate for the missing activity attributed to native Oar1p, the four strains (each expressing FabG1, FabG4, Oar1p or Cta1p) were propagated overnight in liquid SD-Ura medium. Following tenfold serial dilution, cultures were spotted onto solid SD-Ura (glucose) or SCglycerol (glycerol) media, and the plates were incubated at 30°C until single colonies were detectable (Fig. [2](#Fig2){ref-type="fig"}). As anticipated, mutant *oar1*Δ cells expressing Oar1p could form single colonies on glycerol, whereas those cells expressing Cta1p were not able to proliferate on this medium, vindicating the experimental design. Importantly, the results demonstrated that the respiratory deficient phenotype of the *oar1*Δ mutant could be rescued by FabG1 and FabG4, indicating functional complementation.Fig. 2Growth of *S. cerevisiae oar1*Δ mutants expressing *M. tuberculosis* FabG1 or FabG4. Yeast *oar1*Δ cells expressing native mitochondrial 3-oxoacyl-ACP reductase (Oar1p positive control), native peroxisomal catalase A (Cta1p negative control), mitochondrially targeted FabG1 or mitochondrially targeted FabG4 were grown in liquid SD-Ura medium that selected for plasmid presence. Following serial dilution, cells were applied to solid (SD-Ura) glucose or (SCglycerol) glycerol media. The plates were incubated at 30°C until single colonies appeared and recorded photographically. The yPLM strains used were 37, 38, 41 and 43

Yeast *oar1*Δ cells expressing FabG4 contain 3-oxoacyl-thioester reductase activity {#Sec9}
-----------------------------------------------------------------------------------

Soluble protein extracts from BY4741*oar1*Δ cells expressing *M. tuberculosis* FabG1 or FabG4 were examined for 3-oxoacyl-thioester reductase activity using 2-*trans*-hexenoyl-CoA (*trans-*C~6:1(2)~) or 2-*trans*-decenoyl-CoA (*trans*-C~10:1(2)~) as substrates. The reactions additionally included purified protein consisting of the hydratase 2 domain from *Drosophila melanogaster* peroxisomal type 2 multifunctional enzyme (MFE2), which hydrated the substrates to generate the 3-hydroxyacyl-CoA species that could be metabolized, in the reverse reaction, by the 3-oxoacyl-thioester reductases examined. The reactions were monitored spectrophotometrically at wavelengths of 340--385 nm, by following the reduction of NADP^+^ or NAD^+^ to their corresponding protonated species (Gurvitz [@CR19]). Both electron carrier types were considered in this assay, as recent work revealed that 3-oxoacyl-thioester reductase activity might actually depend on NAD(H), poignantly evidenced by the nematode and human 3-oxoacyl-ACP reductases of mitochondrial FASII (Gurvitz [@CR19]; Chen et al. [@CR11]).

To obtain high levels of protein expression from the fatty acid-inducible *CTA1* promoter (Filipits et al. [@CR15]; Rottensteiner et al. [@CR33]), cells were grown overnight on oleic acid medium. The results of the enzyme assays with 2-*trans-*hexenoyl-CoA as substrate and NADP^+^ as cofactor (in the presence of hydratase 2 activity) performed on *oar1*Δ cells over-expressing native Oar1p or Cta1p indicated that any reductase activity present was below the detection limit of the assay used. Recent work on Oar1p by others revealed that its 3-oxoacyl-thioester reductase activity could only be detected in assays performed on a recombinant protein (Chen et al. [@CR11]). Similarly, it was impossible to detect any activity in soluble protein extracts obtained from *oar1*Δ cells over-expressing FabG1 when NADP(H) was supplied as cofactor in the reaction, but this was anticipated since previous measurements were also performed solely on a recombinant protein (Marrakchi et al. [@CR29]). Surprisingly, a volume of 0.1 µl of soluble protein extract containing approximately 5 mg/ml protein from mutant cells over-expressing FabG4 gave rise to an NAD(H)-dependent oxidation of the C~6~ substrate at the rate of 0.21 ± 0.02 (SD, *n* = 3) µmol/mg protein × min^−1^ (Table [2](#Tab2){ref-type="table"}). When the C~10~ substrate was used under the same reaction conditions, the soluble extracts containing FabG4 yielded a rate of 0.25 ± 0.08 (SD, *n* = 3) µmol/mg protein × min^−1^ (Table [2](#Tab2){ref-type="table"}). Further examination of FabG4 extracts with NADP^+^ and C~6~ resulted in a rate of 3.5 ± 0.3 (SD, *n* = 3) nmol/mg protein × min^−1^ (Table [2](#Tab2){ref-type="table"}), indicating that FabG4 might also utilize NADP(H), albeit inefficiently. Hence, heterologous expression of FabG4 in mutant *oar1*Δ cells resulted in protein extracts containing readily detectable levels of 3-oxoacyl-thioester reductase activity.Table 2Enzyme activities in a yeast *oar1*Δ mutant expressing FabG4Substrate3-Oxoacyl-thioester reductase activity (nmol/mg protein × min^−1^)NAD(H)NADP(H)2-*trans-*hexenoyl-CoA210 ± 20^a^3.5 ± 0.32-*trans*-decenoyl-CoA250 ± 80Not tested^a^The values are means ± standard deviations (*n* = 3) and represent averages of measurements using extracts obtained from three independent yeast cultures following overnight oleic acid induction. The yeast strain used was yPLM41

FabG1 and FabG4 restore the assembly of cytochrome complexes in the *oar1*Δ mutant {#Sec10}
----------------------------------------------------------------------------------

Yeast cells carrying a deletion at the *OAR1* gene have previously been shown to lack assembled cytochrome complexes (Schneider et al. [@CR37]). Hence, rescue of *oar1*Δ cells from their fermentative phenotype should be associated with re-assembly of these structures. To verify this recovered function by means of a qualitative assay, the yeast strains described in "[Yeast *oar1*Δ cells expressing FabG4 contain 3-oxoacyl-thioester reductase activity](#Sec9){ref-type="sec"}" were monitored for cytochrome complex assembly using the cold-temperature cuvette method (Lindenmayer and Estabrook [@CR28]). Cell pastes were collected and applied to cuvettes that were then immersed in liquid nitrogen prior to being placed in a spectrophotometer. The result demonstrated that *oar1*Δ cells expressing peroxisomal Cta1p were not efficient at assembling the complete retinue of the cytochrome complexes (e.g., complexes *a* and *a3*; Fig. [3](#Fig3){ref-type="fig"}). On the other hand, the signals representing these complexes were more pronounced in mutant cells expressing native Oar1p or mycobacterial FabG1 and FabG4. Hence, this indicated that the ability of *oar1*Δ mutants to grow on glycerol was coincidental with the recuperation of cytochrome complex assembly in their mitochondria.Fig. 3Spectrophotometric assay for mitochondrial cytochrome complexes. Cell pastes from the indicated strains were collected from liquid cultures that were cultivated overnight in oleic acid medium and applied to the glass face of otherwise aluminum cold-temperature cuvettes that were immersed in liquid nitrogen prior to being placed in a spectrophotometer for analysis. The pastes were scanned at wavelengths between 480 and 640 nm. *Numbers* to the *left* indicate units of absorbance (ABS), those at the *bottom* refer to wavelength in nm. *Peaks* corresponding to known cytochromes are indicated (*letters* with *arrows*). The yPLM strains used were 37, 38, 41 and 43

Expression of FabG1 or FabG4 renews lipoic acid production in the *oar1*Δ mutant {#Sec11}
--------------------------------------------------------------------------------

Previous work demonstrated that the C~8~ octanoic acid product of mitochondrial FASII acts as the starting point for the synthesis of lipoic acid, and that a mutation in any one of the yeast genes encoding mitochondrial FASII enzyme causes a dramatic drop in the levels of lipoic acid (Hiltunen et al. [@CR26]). However, this deficiency can be reversed when such mutants are supplied with known or presumed FASII enzyme activities of the corresponding type. To link FabG1 and FabG4 expression with a rehabilitated FASII system in yeast mitochondria, lipoic acid levels were examined in the four strains using an in vivo growth assay that exploits a lipoic acid-deficient *E. coli* strain (Brody et al. [@CR9]; Hayden et al. [@CR24]). Extracts prepared from the negative control strain expressing Cta1p supported only a nominal growth level of these *E. coli* cells, commensurate with 7 ng lipoic acid present per gram wet weight of yeast cells (Table [3](#Tab3){ref-type="table"}). In contrast, yeast mutant cells expressing native Oar1p produced sufficient amounts of lipoic acid to support levels of bacterial growth equivalent to 193 ng of lipoic acid per gram wet weight. Importantly, expression of FabG1 or FabG4 in the yeast mutant resulted in extracts containing the respective lipoic acid levels of 174 and 164 ng of lipoic acid per gram wet weight, which were over 20-fold higher than the levels of the negative control, thereby underscoring further the function of FabG4 as a putative FASII-like 3-oxoacyl-thioester reductase.Table 3Lipoic acid production in yeast *oar1*Δ mutants expressing the listed proteinsProteinLipoic acid content (ng/g \[wet weight\])Cta1p7 ± 2Oar1p193 ± 7^a^FabG1174 ± 22FabG4164 ± 23^a^The values are means ± standard deviations (*n* = 3) and represent averages of three independent bacterial growth responses. The *S. cerevisiae* yPLM strains used were 37, 38, 41 and 43

Discussion {#Sec12}
==========

The identification of a novel 3-oxoacyl-thioester reductase encoded by the essential mycobacterial gene *fabG4* is described herein. The report takes into account the findings whereby FabG4 (1) restored the respiratory growth of an otherwise obligatory fermentative yeast mutant devoid of Oar1p; (2) contained high levels of 3-oxoacyl-thioester reductase activity; and (3) replaced Oar1p during lipoic acid synthesis. Future experimentation dedicated to knocking out *fabG4* would likely help to elucidate whether FabG4 is in fact vital for *M. tuberculosis* persistence and virulence. Nevertheless, since FabG4 was practically indistinguishable from the essential mycobacterial 3-oxoacyl-AcpM reductase FabG1 within the parameters of phenotype rescue in yeast, it is attractive to speculate that FabG4 might also be involved in some hitherto elusive aspect of fatty acid biosynthesis in *M. tuberculosis*. Additional important results to emerge here regarding FabG1 include the refinement of its in vivo substrate specificities (down to C~4~), as well as exposure of its ability to function in yeast without resorting to protein--protein interactions with other mycobacterial FASII enzymes.

The role of FabG1 has been described previously within the context of mycobacterial FASII, which is outlined in great detail in Takayama et al. ([@CR38]). FASII begins with a C~20~-CoA intermediate emerging from FASI, with additional rounds of C~2~ extensions being undertaken by FASII so as to arrive at the final length (up to C~63~) required for incorporation into mature mycolic acids. In a FASII pre-step, 3-oxoacyl-AcpM synthase mtFabH (see below) converts the incoming C~20~-CoA to a (C~22~) 3-oxoacyl-AcpM based on the availability of C~3~ malonyl-AcpM. Further FASII extensions are effected by two additional 3-oxoacyl-AcpM synthases, represented by KasA and KasB, giving rise to a 3-oxoacyl-AcpM intermediate. This metabolite acts as substrate for the aforementioned FabG1, which reduces the latter intermediary to 3-hydroxyacyl-AcpM, with the concomitant oxidation of NADPH. The subsequent two FASII steps include dehydration and reduction (Takayama et al. [@CR38]).

With reference to the non-rescuing FabG homologs, the published data for FabG2, FabG3 and FabG5 remain rather scant. The crystal structure of FabG3/Rv2002 has been determined, but there are no data available on its physiological function or enzyme activity (Yang et al. [@CR43]). Another homolog, FabG5/Rv2766c, was picked up with additional proteins (including InhA and the isoniazid-sensitive dihydrofolate reductase DfrA) in a screen for proteins capable of interacting with a resin mimicking the isoniazid--NAD/P adduct formed with the active species of isoniazid (Argyrou et al. [@CR1]). Interestingly, isoniazid-sensitive FabG1 itself (Banerjee et al. [@CR4]; Ducasse-Cabanot et al. [@CR14]) was not identified in this search. In the aforementioned scan for genes needed for optimal growth (Sassetti et al. [@CR36]), of the five *fabG* genes only *fabG2/Rv1350* was found to be required for this parameter. Moreover, none of them came up in a transposon-based screen for altered virulence (McAdam et al. [@CR30]), or was upregulated in *M. tuberculosis* treated with isoniazid and other antimicrobials (Betts et al. [@CR6]). Hence, further work will be required to underpin the functions of the remaining FabG homologs. This notwithstanding, it should be noted that since the present study was conducted entirely in a yeast background, the observations presented here may not necessarily apply to mycobacterial biochemistry. In other words, because phenotype rescue could not be achieved with the remaining three homologs, it would be premature to proclaim that they do not in fact play a role in fatty acid biosynthesis.

Returning to the essential requirement of FabG4 for mycobacterial existence, although an *M. tuberculosis* mutant knockout at *fabG4* has been reported previously to be symptomless in the context of survival during infection (Sassetti and Rubin [@CR35]), very important recent studies revealed *fabG4* (as well as *fabG1*, *fabD* and *acpS*, all affiliated with FASII) to be essential, at least in terms of growth of *M. bovis* BCG on Roisin's medium (Beste et al. [@CR5]). Interestingly, the *fabG4* locus (*Rv0242c*) occurs in close proximity to that of *htdX* (*Rv0241c*), whose latter product has been shown recently to act in yeast *hdt2*Δ cells as a physiological 3-hydroxyacyl-thioester dehydratase (Gurvitz et al. [@CR23]). This represents the enzyme activity following FabG in the fatty acid biosynthesis scheme, and the two genes are predicted to occur in a single operon (operonDB; confidence = 84; *n* = 57). Since similar pair arrangements have been observed in *M. tuberculosis* with other genes of mycolic acid biosynthesis, including *Rv1484/inhA* and *Rv1483/fabG1* (Takayama et al. [@CR38]), it is at least plausible that HtdX and FabG4 might also function within a shared FASII-like pathway.

Regarding the issue of whether FabG1 is essential for pathogen survival, this has only recently been resolved. A study dedicated to addressing this specific issue revealed that knocking out the gene for FabG1 in the pathogen was only possible if an additional plasmid-borne gene copy was made available, a procedure formally accepted as genetic proof for the essentiality of this gene (Parish et al. [@CR31]). Although the requirement for FabG1 in *M. tuberculosis* could be compensated by using the homologous protein from *M. smegmatis*, functional complementation of the mycobacterial mutant devoid of its native FabG1 could not be achieved using an ectopically expressed *E. coli* FabG. It was argued that failure to complement the mutant phenotype using the bacterial protein was likely due to structural differences between the bacterial and mycobacterial proteins (Parish et al. [@CR31]), in that the former is not able to accommodate long-chain fatty acids or undertake the suggested specific protein--protein interactions necessary for FASII (Veyron-Churlet et al. [@CR40], [@CR41]).

Hence, the finding here that FabG1 could alleviate the growth phenotype of *oar1*Δ mutant cells was remarkable in light of the conclusions drawn regarding the central position of FabG1 in the complex presumed to exist within the structure of mycobacterial FASII (Veyron-Churlet et al. [@CR40]). Using the yeast two-hybrid approach, native FabG1 was shown to interact only very weakly with the aforementioned FabH, albeit subsequent co-immunoprecipitation failed to confirm this putative interaction altogether. Nevertheless, mutant versions of FabG1 were constructed so that they failed to form the native FabG1 multimer; these displayed more extensive protein--protein interactions, namely with the previously mentioned KasA, KasB, and FabH. Based on the results with these mutant FabG1 monomers, the authors concluded that the wild-type FabG1 monomer must also interact with each of the aforementioned condensing enzymes in the native state, and that the high propensity of these monomers to multimerize helps maintain the macromolecular organization of FASII. Since expression of these FabG1 mutants in *M. tuberculosis* appeared to block FASII, presumably by forming unproductive FabG1 multimers, this led to the suggestion that the quaternary structure of FabG1 is critical for a functional FASII complex (Veyron-Churlet et al. [@CR40]). The conclusion that FabG1 represents a pivotal interacting protein that is vital for maintaining FASII complexes in *M. tuberculosis* is difficult to reconcile with the observations made here, whereby FabG1 could function in yeast FASII to 90% efficiency (Table [3](#Tab3){ref-type="table"}) in an environment within which it has clearly not evolved to form highly specific protein--protein interactions.

A further point of contention regarding FabG1 is its physiological substrate specificity. Previous work on recombinant FabG1 showed that it was active in vitro using C~4~ acetoacetyl-CoA as substrate (Banerjee et al. [@CR4]; Ducasse-Cabanot et al. [@CR14]). However, other studies found that FabG1 preferentially acts on long-chain C~8--20~ CoA substrates, and that it metabolizes the C~4~ substrate only poorly (Marrakchi et al. [@CR29]). Unfortunately, even following extensive over-expression in cells grown on oleic acid medium, the enzyme assay used here failed to detect any reductase activity for FabG1 using C~6~ or C~10~ substrates. Nevertheless, it can still be concluded that, at least within an in vivo yeast context, FabG1 was almost as efficient as native Oar1p in metabolizing short-chain C~4--8~ substrates, despite *fabG1* being expressed at only modest levels commensurate with glucose derepression. Herein lays one of the major advantages of using yeast for examining the in vivo efficacy of enzymes for substrates that are otherwise not metabolized facilely in vitro. It is predicted that yeast FASII mutants will continue to serve as a convenient tool for identifying novel pathogen proteins.
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ACP

:   Acyl carrier protein

AcpM

:   Mycobacterial ACP

BCG

:   Bacillus Calmette-Guérin

FAS

:   Fatty acid synthase

FASI

:   Type 1 associative FAS

FASII

:   Type 2 dissociative FAS

MLS

:   Mitochondrial leader sequence

ORF

:   Open reading frame

PCR

:   Polymerase chain reaction

MFE2

:   Peroxisomal type 2 multifunctional enzyme

[^1]: Communicated by G. Klug.
